SynAct PharmaSynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients

SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

September 23, 2020Swedish version of press release published earlier today. SynAct Pharma initierar fas II-studie med AP1189 för behandling av ARDS i COVID-19-patienter
September 23, 2020SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients
September 3, 2020SynAct Pharma informs that the recruitment to part 1 in the Clinical Phase II study with AP1189 in Rheumatoid Arthritis is completed
September 1, 2020SynAct Pharma Informs about Termination of Coverage Agreement with Redeye

All press releases

News

April 2, 2020BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)
April 1, 2020Synact Pharma in spotlightanalysen (in Swedish)
October 28, 2019Redeye: Adding an indication
July 5, 2019Kliniska bevis för behandlingseffekter av melanokortiner vid reumatoid artrit

Calendar

October 8, 2020Sedermeradagen Gothenburg
October 26, 2020 - October 28, 2020Bio Europe 2020
November 16, 2020Sedermeradagen Stockholm

Subscribe to our press releases